NeuroSense Therapeutics Ltd. (NRSN) stock
NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
$1.37−0.14 (-9.27%)
Close on Nov 18, 2026Market cap $2.52MP/E –Yield –
NeuroSense Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was -$7.67M. The highest annual figure on record is -$582.00K in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.67M | – |
| FY2024 | Dec 31, 2024 | -$10.14M | – |
| FY2023 | Dec 31, 2023 | -$8.35M | – |
| FY2022 | Dec 31, 2022 | -$7.62M | – |
| FY2021 | Dec 31, 2021 | -$1.54M | – |
| FY2020 | Dec 31, 2020 | -$695.00K | – |
| FY2019 | Dec 31, 2019 | -$582.00K | – |
See a number that looks wrong?